EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his po...
During September 2025, the number of shares and votes in EQL Pharma AB (“EQL Pharma”) has increased as a result of the exercise of warrants issued pursuant to two warrant programs adopted by the an...
EQL's key product Mellozzan[®] (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan[®] successfully in Germany, among ot...
Interim Report Q2
Interim Report Q3
Year End Report Q4
